Medline Inc. (MDLN) company profile
Close on Nov 16, 2026Market cap $51.50BP/E –Yield –
About Medline
Surgical & Medical Instruments & Apparatus, SIC 3841
Medline Inc. manufactures and distributes medical-surgical supplies and provides healthcare supply chain management services. The company conducts business through two reportable segments: Medline Brand and Supply Chain Solutions. Through its Medline Brand segment, it provides proprietary items spanning patient front-line care, surgical and perioperative environments, and laboratory diagnostics, including wound care supplies, examination gloves, surgical procedure kits, and diagnostic instruments. Through its Supply Chain Solutions segment, Medline distributes third-party medical products alongside logistics optimization, third-party warehousing, consulting, and inventory management services. Its customers encompass all healthcare care settings, including hospitals, ambulatory surgery centers, physician clinics, and post-acute facilities.
The company employs over 45,000 workers worldwide, with more than 26,000 located in the United States and substantial teams in countries such as Mexico, the Dominican Republic, India, Canada, Slovakia, France, China, Japan, Germany, and Australia. Medline operates 30 manufacturing plants, 24 of which are in North America, and maintains 70 global distribution centers, warehouses, and transit hubs, with 45 across the United States supported by a private transport fleet exceeding 2,100 delivery trucks. The provided text does not mention the location of its headquarters.
Summary of the business section of Medline's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Medline Inc.
- Founded
- 1966
- Headquarters
- Northfield, IL
- Address
- 3 Lakes Drive 60093
- Phone
- (847) 949-3000
- Website
- www.medline.com
- Employees
- 45,000, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- MDLN
- Exchange
- Nasdaq
- IPO date
- Dec 18, 2025
- Shares outstanding
- 1.31B, Aug 3, 2026
- Public float
- $13.00B, Dec 17, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 2046386
- CUSIP
- 58507V107
- ISIN
- US58507V1070
- FIGI
- BBG01Y6778L4
- Share class FIGI
- BBG01Y6779J5
- LEI
- 984500FAN6J1P8566D43
- EIN
- 33-1845288
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James M. Boyle | Chief Executive Officer, Director | 3,084,818 |
| Alexander M. Liberman | Chief Legal Officer | 1,270,811 |
| Amanda H. Laabs | Chief Product Officer | 795,096 |
| Douglas P. Golwas | Chief Commercial Officer | 1,323,309 |
| Stephen L. Miller | Chief Operating Officer | 23,899 |
| Christopher P. Shryock | Chief Human Resources Officer | 11,031 |
| Michael B. Drazin | Chief Financial Officer | 509,927 |
| William J. Abrams | See Remarks | 542,881 |
| Jessi L. Corcoran | Principal Accounting Officer | 5,000 |
| James M. Pigott | President | 1,206,467 |
| Thomas W. Sweet | Director | 17,800 |
| Todd M. Bluedorn | Director | 15,732 |
| Richard A. Galanti | Director | 16,392 |
| Patrick J. Healy | Director | 1,599,493 |
| Robert R. Schmidt | Director | – |
| Stephen H. Wise | Director | – |
| Charles N. Mills | Director | 2,643,315 |
| Andrew J. Mills | Director | 2,616,861 |
| Anushka M. Sunder | Director | – |
| Jacob Best | Director | – |
| Joseph Baratta | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.86M | $61.84M | $4.62M | $102 | $101 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| James M. Boyle Chief Executive Officer | $1.25M | $1.18M | $1.41M | $23.35K | $3.86M | -10% |
| Michael B. Drazin Chief Financial Officer | $810.00K | $956.85K | $763.12K | $27.29K | $2.56M | -7% |
| James M. Pigott President | $1.10M | $0 | $930.57K | $8.88M | $10.91M | +176% |
| Douglas P. Golwas Chief Commercial Officer | $800.00K | $956.85K | $772.41K | $25.03K | $2.55M | -7% |
| Stephen L. Miller Chief Operating Officer | $800.00K | $956.85K | $676.78K | $9.14K | $2.44M | -43% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 18, 2025
- Offer price
- $29.00
- Securities offered
- 216,034,482
- Gross proceeds
- $6.26B
- Exchange
- Nasdaq
- First trading day
- Dec 17, 2025
- First-day close
- $41.00+41.4%
- Lock-up ends (est.)
- Jun 15, 2026
“Per Share Total Initial public offering price $ 29.00 $ 6,264,999,978.00 Underwriting discounts and commissions (1) $ 0.63173 $ 136,475,463.31 Proceeds, before expenses, to Medline Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 18, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 17, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?